Emergent BioSolutions Inc.
As of Oct 22, 2026, Emergent BioSolutions is in Stage 4, the downtrend phase, now in week 15 (since Jul 14, 2026). It closed at $6.23, 55.2% below its 52-week high and below its 200-day average, which is falling.
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is EBS early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
EBS among Drug Manufacturers - Specialty & Generic47th of 84 by relative strength
All 84 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CPIX | Stage 2 · wk 23 | 98 | +6.8% |
| 2 | ETON | Stage 2 · wk 30 | 97 | −10.1% |
| 3 | ANIK | Stage 2 · wk 15 | 96 | +3.5% |
| 4 | IRWD | Stage 3 · wk 3 | 96 | −16.4% |
| 5 | TEVA | Stage 2 · wk 9 | 95 | +3.1% |
| 6 | AMRX | Stage 2 · wk 19 | 95 | +5.9% |
| 7 | KNSA | Stage 2 · wk 73 | 95 | +6.2% |
| 8 | AMLX | Stage 2 · wk 15 | 93 | −6.6% |
| …47 | EBS | Stage 4 · wk 15 | 31 | −6.6% |
Emergent BioSolutions: quick answers
What stage is Emergent BioSolutions in?
As of Oct 22, 2026, Emergent BioSolutions (EBS) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 14, 2026 and is in week 15. What the four stages mean
Is Emergent BioSolutions in an uptrend?
No. Emergent BioSolutions is in a Stage 4 downtrend. It trades 24.0% below its 200-day average, which is falling.
How far is Emergent BioSolutions from its 52-week high?
Emergent BioSolutions closed at $6.23 on Oct 22, 2026, 55.2% below its 52-week high of $13.90. Its 52-week low is $4.45.
How has Emergent BioSolutions performed over the past year?
As of Oct 22, 2026, Emergent BioSolutions is down 34.1% over the past year and down 50.2% so far in 2026.
Which sector and industry is Emergent BioSolutions in?
Emergent BioSolutions is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - Specialty & Generic
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.